Active Investments

	Aerie Pharmaceuticals Aerie Pharmaceuticals is a privately held, clinical-stage biotechnology company dedicated to the discovery and development of novel treatments for glaucoma. The Company is located in Bridgewater New Jersey and Research Triangle Park North Carolina
	Alvine Alvine is a clinical stage company developing biologics to target autoimmune/inflammatory diseases. The company’s lead product candidate, ALV003, is a mixture of two proteases engineered to degrade gluten. Gluten is the difficult to digest protein found in wheat, rye, and barley that triggers celiac disease in genetically susceptible individuals.
	Amarin Amarin is a clinical-stage biopharmaceutical company focused on improving the treatment of cardiovascular disease. Amarin’s lead candidate, AMR101, is currently being studied in two concurrently run pivotal Phase 3 trials. The company’s cardiovascular programs capitalize on its expertise in the field of lipid science and the known therapeutic benefits of essential fatty acids in treating cardiovascular disease. (Nasdaq: AMRN)
	Anthera Pharmaceuticals Anthera is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including cardiovascular and autoimmune diseases. Anthera has one Phase 3 clinical program, A-002, and two Phase 2 clinical programs, A-623 and A-001. (Nasdaq: ANTH)
	Ascenta Therapeutics Ascenta is a clinical stage biopharmaceutical company dedicated to the discovery and development of new medicines to treat cancer. Ascenta’s current focus is a portfolio of novel, orally-active, small molecule drugs that restore the natural potential for cancer cells to undergo cell death (apoptosis). Ascenta’s lead drug candidate, AT-101) is currently in Phase 2b clinical trials.
	Catalyst Biosciences Catalyst is a drug discovery and development company that is creating novel catalytic biopharmaceutical products based on engineered human proteases. The Company is developing proteases for the treatment of a broad range of diseases with a strong focus on hemostasis and inflammation. Catalyst is developing both natural and engineered human proteases "Alterase Therapeutics" to treat major diseases.
	Cebix Cebix is a biopharmaceutical company focused on the development of chronic replacement therapy based on human proinsulin C-peptide for the treatment of type 1 diabetic neuropathy. The company has recently developed a once weekly dosage form which it is currently advancing into clinical trials. Cebix has met with the FDA and reached agreement with the Agency on its development plans in diabetic neuropathy.
	Durata Therapeutics Durata is a biopharmaceutical company addressing the growing need for new antibiotics to treat infectious diseases. Durata’s lead product candidate, dalbavancin, is in late-stage clinical development, and the company also has two antibiotic programs in earlier-stage, preclinical research.
	Hyperion Therapeutics Hyperion is a pharmaceutical company focused on the development of treatments that address critical unmet needs in the areas of gastroenterology and hepatology. Hyperion aims to build its portfolio of products through partnership and in-licensing. Hyperion is currently focused on the development of one compound, glycerol phenybutyrate (HPN-100), for both urea cycle disorders (UCD) and hepatic encephalopathy (HE). The compound is currently in Phase 3 studies for UCD and in Phase 2 studies for HE.
	InteKrin Therapeutics InteKrin is a clinical-stage biopharmaceutical company focused on developing and commercializing breakthrough therapeutics for neuroendocrine, metabolic, and immune disorders. The company is in the process of in-licensing early- and late-stage compounds that have the potential to unlock the complex hormonal relationship between metabolism, insulin resistance, and obesity. Its lead drug candidate, INT131, is currently in Phase II clinical trials for treatment of Type 2 diabetes mellitus.
	Intellikine Intellikine is a clinical-stage company focused on the discovery and development of small molecule drugs targeting the PI3K/mTOR pathway. The company’s most advanced program, INK128, a selective TOR1/2 inhibitor for the treatment of cancer, is currently in Phase 1 clinical trials in patients with advanced solid tumors.
	KaloBios KaloBios is a monoclonal company using its biologic capabilities and its proprietary platform technology to develop first-in-class human antibody therapeutics. The company’s multiple programs have completed seven Phase 1 or 2 clinical trials for Pseudomonas aeruginosa infections, cystic fibrosis patients, intensive care patients on a ventilator, inflammatory conditions and hematologic malignancies.
	Marinus Pharmaceuticals Marinus is a specialty pharmaceutical company dedicated to the reformulation, development, and commercialization of novel drugs to treat serious neurological, psychiatric, and pain disorders. The company’s lead product is a first in class therapy for epilepsy.
	NextWave Pharmaceuticals NextWave is a CNS–focused specialty pharmaceutical company that develops and commercializes unique products utilizing proprietary drug delivery technology to address unmet needs in key therapeutic areas — with particular emphasis on the treatment of ADHD and related disorders.
	Ocera Ocera is a biopharmaceutical company focused on the licensing, development and commercialization of proprietary compounds to treat a broad range of gastrointestinal and liver diseases. Ocera is pursuing the development of AST-120 in Crohn's disease and other gastrointestinal and liver diseases including pouchitis, hepatic encephalopathy, irritable bowel syndrome and proton pump inhibitor-resistant gastroesophageal reflux disease.
	SARcode Bioscience SARcode Biosciences is a venture-backed biopharmaceutical company focused on the development of best in class small molecule LFA-1 antagonists as novel nonsteroidal immunomodulators/anti-inflammatory agents for the treatment of Tcell mediated inflammatory diseases. The Company’s lead program, targeting dry eye disease, is preparing to enter Phase III trials.
	Sorbent Therapeutics Sorbent is a biopharmaceutical company focused on the development of adaptable non-absorbed polymeric drugs to satisfy unmet clinical needs in large markets such as End Stage Renal Disease (ESRD), congestive heart failure (CHF), chronic kidney disease (CKD), and hypertension.
	Trius Therapeutics Trius is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening infections. Trius is currently conducting Phase 3 trials for torezolid phosphate (TR-701), an IV and orally administered second generation oxazolidinone, for the treatment of serious gram-positive bacterial infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). (Nasdaq: TSRX)